Abstract 292P
Background
Cervical cancer is the second most common malignancy among women in poor countries, according to the World Health Organization. According to some writers, cervical cancer is the second- or third-leading cause of mortality for women over 30 in Uzbekistan. Statistics on cervical cancer are hotly debated because not all women visit a doctor. On the pathologist's table, the diagnosis is frequently made.
Methods
During a regular checkup, 92 women between the ages of 25 and 48 were seen at the antenatal clinic of hospital No. 1g. Using liquid cytology and Pap test technologies, a screening cytological examination was performed on all women. According to clinical recommendations, the PAP test classes were interpreted as follows: class 1 — normal; class 2 — inflammatory type; class 3 — dyskaryosis; class 4 — cells suggestive for cancer or carcinoma; and class 5 — malignancy.
Results
50 women had normal cytological screening results from Pap tests, while 36 had inflammatory type outcomes. There was an inadequate type of sample in 6 women. A negative result of cytological screening by liquid cytology was found in 44 women; 36 women had cytograms that were within the normal range; and 10 women had atypical cells of stratified squamous epithelium that were of unknown significance. Additionally, 2 women developed epithelial squamous lesions of low severity. Compared to liquid cytology, which had a sensitivity of 77.0%, the Pap test had a sensitivity of 33.0%. While liquid cytology had a specificity of 72.0%, the Pap test had a higher specificity of 87.0%. Liquid cytology and the predictive value of a positive Pap test were comparable. Compared to the PAP test, the liquid cytology test had a better predictive value for a negative outcome.
Conclusions
The study's findings revealed that both approaches to early cervical cancer diagnosis estimate the incidence of the condition equally. In addition, liquid cytology makes it more probable to produce a positive result in the group of patients who actually have the disease and, to a lesser extent, in those who do not. When employing the liquid cytology method, the prognosis of the likelihood of the disease being absent in patients with a negative result was higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract